For the twelve months ended Aug 31, 2026, Biomerica Inc. reported $4.34M of revenue and -$5.01M of net income.
BMRA revenue was $1.26M in fiscal Q1 2027 (ended Aug 31, 2026), down 8.3% from a year earlier and up 44.6% from the prior quarter. For the full fiscal 2026 it was $4.45M, down 16.2% from fiscal 2025. Compound annual growth was -9.2% over 5 years and -1.4% over 10 years. It rose in 5 of the last 10 fiscal years.
BMRA net income was -$1.23M in fiscal Q1 2027 (ended Aug 31, 2026), compared with $2.0K a year earlier. For the full fiscal 2026 it was -$3.77M, compared with -$4.97M in fiscal 2025.
BMRA diluted EPS was -$0.37 in fiscal Q1 2027 (ended Aug 31, 2026), compared with $0.00 a year earlier. For the full fiscal 2026 it was -$1.30, compared with -$2.16 in fiscal 2025.
| Line item | May 31, 2026 | May 31, 2025 | May 31, 2024 | May 31, 2023 | May 31, 2022 | May 31, 2021 | May 31, 2020 | May 31, 2019 | May 31, 2018 | May 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.45M | $5.31M | $5.42M | $5.34M | $18.87M | $7.20M | $6.69M | $5.20M | $5.56M | $5.79M |
| Cost of revenue | $4.09M | $4.81M | $4.80M | $4.89M | $15.89M | $6.83M | $4.95M | $3.91M | $3.81M | $3.77M |
| Gross profit | $362.0K | $498.0K | $611.0K | $446.0K | $2.98M | $366.3K | $1.74M | $1.29M | $1.75M | $2.02M |
| Research and development | $788.0K | $1.02M | $1.49M | $1.58M | $1.81M | $2.19M | $1.93M | $1.68M | $1.40M | $1.13M |
| Selling, general and admin | $4.89M | $4.61M | $5.49M | $6.08M | $5.70M | $5.67M | $2.55M | $2.03M | $1.84M | $1.85M |
| Operating income | -$5.32M | -$5.14M | -$6.37M | -$7.22M | -$4.53M | -$7.50M | -$2.74M | -$2.41M | -$1.48M | -$954.6K |
| Interest expense | - | - | - | - | - | $367 | $9 | $47 | $37 | $282 |
| Pre-tax income | -$3.75M | -$4.97M | -$5.94M | -$7.09M | -$4.51M | -$7.43M | -$2.67M | -$2.37M | -$1.43M | -$908.6K |
| Income tax | $23.0K | $1.0K | $42.0K | $51.0K | $24.0K | $13.1K | $7.4K | $24.2K | $31.8K | - |
| Net income | -$3.77M | -$4.97M | -$5.98M | -$7.14M | -$4.53M | -$7.45M | -$2.68M | -$2.39M | -$1.47M | -$908.6K |
| EPS, basic | -$1.30 | -$2.16 | -$2.84 | -$0.50 | -$0.36 | -$0.62 | -$0.26 | -$0.26 | -$0.17 | -$0.11 |
| EPS, diluted | -$1.30 | -$2.16 | -$2.84 | -$0.50 | -$0.36 | -$0.62 | -$0.26 | -$0.26 | -$0.17 | -$0.11 |
| Diluted shares | 2.9M | 2.3M | 2.1M | 14.2M | 12.7M | 11.9M | 10.2M | 9.2M | 8.6M | 8.3M |
| Line item | May 31, 2026 | May 31, 2025 | May 31, 2024 | May 31, 2023 | May 31, 2022 | May 31, 2021 | May 31, 2020 | May 31, 2019 | May 31, 2018 | May 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.31M | $2.40M | $4.17M | $9.72M | $5.92M | $4.20M | $8.64M | $686.8K | $1.20M | $1.23M |
| Receivables | $785.0K | $731.0K | $947.0K | $722.0K | $774.0K | $1.46M | $1.77M | $1.45M | $799.9K | $1.06M |
| Inventory | $1.71M | $1.49M | $2.38M | $2.06M | $2.42M | $3.21M | $2.85M | $2.15M | $2.18M | $1.73M |
| Current assets | $4.02M | $4.88M | $7.73M | $12.80M | $9.43M | $9.23M | $14.77M | $4.49M | $4.48M | $4.21M |
| Total assets | $6.76M | $5.95M | $9.25M | $14.45M | $11.37M | $11.82M | $17.26M | $5.25M | $5.22M | $5.02M |
| Current liabilities | $2.48M | $1.74M | $2.20M | $1.95M | $2.01M | $1.30M | $1.48M | $1.26M | $896.8K | $528.9K |
| Total liabilities | $4.13M | $1.84M | $2.66M | $2.73M | $3.05M | $2.59M | $3.05M | $1.26M | - | - |
| Shareholders' equity | $2.63M | $4.11M | $6.59M | $11.72M | $8.32M | $9.23M | $14.21M | $3.98M | $4.33M | $4.49M |
| Line item | May 31, 2026 | May 31, 2025 | May 31, 2024 | May 31, 2023 | May 31, 2022 | May 31, 2021 | May 31, 2020 | May 31, 2019 | May 31, 2018 | May 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.42M | -$3.84M | -$5.36M | -$5.47M | -$479.0K | -$5.25M | -$4.30M | -$2.24M | -$1.17M | -$722.9K |
| Capital expenditures | - | - | $51.0K | $64.0K | $57.0K | $135.9K | $33.6K | $101.1K | $130.3K | $96.1K |
| Free cash flow | - | - | -$5.41M | -$5.54M | -$536.0K | -$5.39M | -$4.33M | -$2.35M | -$1.30M | -$818.9K |
| Investing cash flow | -$1.0K | -$37.0K | -$115.0K | -$78.0K | -$170.0K | -$295.6K | -$118.9K | -$171.1K | -$130.3K | -$96.1K |
| Financing cash flow | $2.33M | $2.11M | -$81.0K | $9.39M | $2.39M | $1.11M | $12.37M | $1.91M | $1.29M | $157.7K |
| Stock-based compensation | $476.0K | $460.0K | $837.0K | $1.19M | $1.26M | - | - | - | - | - |
| Depreciation and amortization | $77.0K | $87.0K | $81.0K | $84.0K | $339.0K | $105.0K | $105.3K | $101.2K | $111.1K | $144.9K |
| Line item | May 31, 2026 | May 31, 2025 | May 31, 2024 | May 31, 2023 | May 31, 2022 | May 31, 2021 | May 31, 2020 | May 31, 2019 | May 31, 2018 | May 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -16.2% | -1.9% | 1.4% | -71.7% | 162.1% | 7.6% | 28.7% | -6.5% | -3.9% | 12.7% |
| Gross margin | 8.1% | 9.4% | 11.3% | 8.4% | 15.8% | 5.1% | 26.0% | 24.8% | 31.5% | 34.9% |
| Operating margin | -119.5% | -96.7% | -117.6% | -135.3% | -24.0% | -104.2% | -41.0% | -46.4% | -26.6% | -16.5% |
| Net margin | -84.8% | -93.6% | -110.4% | -133.7% | -24.0% | -103.4% | -40.0% | -46.0% | -26.3% | -15.7% |
| Free cash flow margin | - | - | -99.9% | -103.7% | -2.8% | -74.8% | -64.7% | -45.1% | -23.4% | -14.1% |
| Return on equity | -143.5% | -121.1% | -90.7% | -60.9% | -54.4% | -80.7% | -18.8% | -60.1% | -33.9% | -20.2% |
| Return on assets | -55.9% | -83.7% | -64.6% | -49.4% | -39.8% | -63.0% | -15.5% | -45.6% | -28.1% | -18.1% |
| Current ratio | 1.62 | 2.80 | 3.51 | 6.58 | 4.69 | 7.10 | 10.00 | 3.56 | 5.00 | 7.96 |
| Line item | Aug 31, 2026 | May 31, 2026 | Feb 28, 2026 | Nov 30, 2025 | Aug 31, 2025 | May 31, 2025 | Feb 28, 2025 | Nov 30, 2024 | Aug 31, 2024 | May 31, 2024 | Feb 29, 2024 | Nov 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.26M | $875.0K | $987.0K | $1.21M | $1.38M | $749.0K | $1.12M | $1.64M | $1.81M | $1.12M | $1.02M | $1.57M |
| Cost of revenue | $1.16M | $946.0K | $1.03M | $1.16M | $956.0K | $993.0K | $1.10M | $1.20M | $1.52M | $1.10M | $1.17M | $1.24M |
| Gross profit | $103.0K | -$71.0K | -$44.0K | $51.0K | $424.0K | -$244.0K | $19.0K | $437.0K | $289.0K | $20.0K | -$149.0K | $325.0K |
| Research and development | $206.0K | $205.0K | $178.0K | $193.0K | $212.0K | $252.0K | $217.0K | $257.0K | $297.0K | $265.0K | $343.0K | $412.0K |
| Selling, general and admin | $1.12M | $1.26M | $1.08M | $1.23M | $1.33M | $1.07M | $1.01M | $1.17M | $1.36M | $1.28M | $1.51M | $1.52M |
| Operating income | -$1.23M | -$1.53M | -$1.30M | -$1.37M | -$1.12M | -$1.56M | -$1.21M | -$993.0K | -$1.37M | -$1.53M | -$2.00M | -$1.61M |
| Pre-tax income | -$1.23M | -$1.14M | -$1.30M | -$1.31M | $5.0K | -$1.54M | -$1.17M | -$953.0K | -$1.31M | -$1.41M | -$1.91M | -$1.50M |
| Income tax | $6.0K | $6.0K | $8.0K | $5.0K | $3.0K | $5.0K | -$4.0K | -$3.0K | $4.0K | $7.0K | $4.0K | $8.0K |
| Net income | -$1.23M | -$1.15M | -$1.31M | -$1.32M | $2.0K | -$1.54M | -$1.16M | -$950.0K | -$1.32M | -$1.42M | -$1.92M | -$1.51M |
| EPS, basic | -$0.37 | -$0.41 | -$0.44 | -$0.45 | $0.00 | -$0.99 | -$0.48 | -$0.06 | -$0.63 | - | -$0.11 | -$0.09 |
| EPS, diluted | -$0.37 | -$0.41 | -$0.44 | -$0.45 | $0.00 | -$0.99 | -$0.48 | -$0.06 | -$0.63 | - | -$0.11 | -$0.09 |
| Diluted shares | 3.3M | - | 3.0M | 2.9M | 2.6M | - | 2.4M | 2.1M | 2.1M | - | 16.8M | 16.8M |
| Line item | Aug 31, 2026 | May 31, 2026 | Feb 28, 2026 | Nov 30, 2025 | Aug 31, 2025 | May 31, 2025 | Feb 28, 2025 | Nov 30, 2024 | Aug 31, 2024 | May 31, 2024 | Feb 29, 2024 | Nov 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.73M | $1.31M | $1.34M | $2.54M | $3.05M | $2.40M | $3.06M | $2.37M | $2.82M | $4.17M | $5.32M | $7.13M |
| Receivables | $897.0K | $785.0K | $941.0K | $947.0K | $1.21M | $731.0K | $1.27M | $1.33M | $1.55M | $947.0K | $1.13M | $1.07M |
| Inventory | $1.63M | $1.71M | $1.65M | $1.52M | $1.47M | $1.49M | $1.66M | $1.79M | $1.94M | $2.38M | $2.13M | $1.84M |
| Current assets | $5.41M | $4.02M | $4.12M | $5.19M | $5.90M | $4.88M | $6.20M | $5.95M | $6.45M | $7.73M | $8.85M | $10.27M |
| Total assets | $8.07M | $6.76M | $4.88M | $6.03M | $6.85M | $5.95M | $7.38M | $7.27M | $7.87M | $9.25M | $10.34M | $11.83M |
| Current liabilities | $2.84M | $2.48M | $1.56M | $1.60M | $1.69M | $1.74M | $1.65M | $1.88M | $2.15M | $2.20M | $1.99M | $1.82M |
| Total liabilities | $4.42M | $4.13M | $1.56M | $1.60M | $1.70M | $1.84M | $1.84M | $2.16M | $2.52M | $2.66M | $2.53M | $2.45M |
| Shareholders' equity | $3.65M | $2.63M | $3.32M | $4.43M | $5.16M | $4.11M | $5.53M | $5.11M | $5.35M | $6.59M | $7.81M | $9.38M |
| Line item | Aug 31, 2026 | May 31, 2026 | Feb 28, 2026 | Nov 30, 2025 | Aug 31, 2025 | May 31, 2025 | Feb 28, 2025 | Nov 30, 2024 | Aug 31, 2024 | May 31, 2024 | Feb 29, 2024 | Nov 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$802.0K | -$912.0K | -$1.25M | -$991.0K | -$268.0K | -$662.0K | -$1.04M | -$791.0K | -$1.34M | -$1.04M | -$1.80M | -$842.0K |
| Capital expenditures | - | - | - | - | - | - | - | - | - | $24.0K | $0 | $6.0K |
| Free cash flow | - | - | - | - | - | - | - | - | - | -$1.07M | -$1.80M | -$848.0K |
| Investing cash flow | - | $18.0K | - | - | - | $0 | -$4.0K | - | - | -$24.0K | -$16.0K | -$12.0K |
| Financing cash flow | $2.23M | $871.0K | $61.0K | $482.0K | $920.0K | -$5.0K | $1.74M | - | - | - | - | - |
| Stock-based compensation | $134.0K | $91.0K | $135.0K | $117.0K | $133.0K | $108.0K | $120.0K | $155.0K | $77.0K | $204.0K | $341.0K | $122.0K |
| Depreciation and amortization | $15.0K | $17.0K | $20.0K | $20.0K | $20.0K | $23.0K | $21.0K | $22.0K | $21.0K | $22.0K | $20.0K | $18.0K |
| Line item | Aug 31, 2026 | May 31, 2026 | Feb 28, 2026 | Nov 30, 2025 | Aug 31, 2025 | May 31, 2025 | Feb 28, 2025 | Nov 30, 2024 | Aug 31, 2024 | May 31, 2024 | Feb 29, 2024 | Nov 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -8.3% | 16.8% | -11.8% | -26.0% | -23.6% | -32.9% | 10.0% | 4.4% | 5.5% | 0.7% | -8.5% | 5.7% |
| Gross margin | 8.1% | -8.1% | -4.5% | 4.2% | 30.7% | -32.6% | 1.7% | 26.7% | 16.0% | 1.8% | -14.7% | 20.7% |
| Operating margin | -97.0% | -175.2% | -131.5% | -113.5% | -81.0% | -208.8% | -108.1% | -60.7% | -75.7% | -136.9% | -196.7% | -102.6% |
| Net margin | -97.4% | -130.9% | -132.9% | -109.1% | 0.1% | -206.1% | -103.9% | -58.1% | -72.8% | -127.3% | -188.6% | -96.2% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | -95.7% | -177.1% | -54.1% |
| Current ratio | 1.91 | 1.62 | 2.64 | 3.25 | 3.48 | 2.80 | 3.76 | 3.17 | 3.00 | 3.51 | 4.44 | 5.63 |
Source: XBRL data Biomerica Inc. files with the SEC, latest filing dated Oct 15, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| BMRA | $4.34M | -11.2% | -$5.01M | -115.5% | $7.4M |
| IDXX | $4.66B | +11.9% | $1.18B | 25.4% | $52.84B |
| LNTH | $1.56B | +2.4% | $269.90M | 17.3% | $6.57B |
| ORKA | - | - | -$132.89M | - | $6.36B |
| NEOG | $883.99M | -0.3% | -$56.10M | -6.3% | $2.55B |
| CLDX | $158.0K | -93.9% | -$309.06M | -195608.9% | $2.22B |
| NTLA | $52.89M | -8.1% | -$426.14M | -805.7% | $1.56B |
| QDEL | $2.59B | -4.5% | -$369.20M | -14.2% | $880.5M |
| ACHV | - | - | -$114.04M | - | $656.5M |